About PostEra
PostEra is a company based in London (United Kingdom) founded in 2019 by Aaron Morris, Alpha Lee, and Matthew Robinson. PostEra has raised $26.2 million across 2 funding rounds from investors including The Clermont, Breyer Capital and Lifeforce Capital. The company has 3 employees as of October 31, 2021. PostEra offers products and services including Proton and PostEra Pipeline. PostEra operates in a competitive market with competitors including Insitro, Certara, HotSpot Therapeutics, CytoReason and GRO Biosciences, among others.
- Headquarter London, United Kingdom
- Employees 3 as on 31 Oct, 2021
- Founders Aaron Morris, Alpha Lee, Matthew Robinson
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Postera Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$26.2 M (USD)
in 2 rounds
-
Latest Funding Round
$26.05 M (USD), Series A
Jan 11, 2022
-
Investors
The Clermont
& 9 more
-
Employee Count
3
as on Oct 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PostEra
PostEra offers a comprehensive portfolio of products and services, including Proton and PostEra Pipeline.
AI tool for accelerating medicinal chemistry in drug discovery processes.
Platform for managing and advancing drug discovery pipelines.
People of PostEra
Unlock access to complete
Funding Insights of PostEra
PostEra has successfully raised a total of $26.2M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $26.05 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PostEra
PostEra has secured backing from 10 investors, including venture fund and angel investors. Prominent investors backing the company include The Clermont, Breyer Capital and Lifeforce Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward Singapore by The Clermont.
|
Locked | Locked | Locked | |
|
Venture capital firm
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare startups
|
Locked | Locked | Locked |
Investor details for PostEra
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PostEra
Investment portfolio details for PostEra
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PostEra
Detailed financials for PostEra
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Postera Comparisons
Peer comparison for PostEra
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PostEra
PostEra operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, Certara, HotSpot Therapeutics, CytoReason and GRO Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Provider of a platform for in silico drug discovery and consulting services
|
|
| Locked | Locked | Locked |
Developer of a platform for protein function analysis
|
|
| Locked | Locked | Locked |
Immune system-based drugs are discovered via biological data analytics.
|
|
| Locked | Locked | Locked |
Synthetic biology tools are developed via genetic code recoding techniques.
|
|
| Locked | Locked | Locked |
Anti-cancer small molecules are developed to target drug resistance pathways.
|
Detailed competitors of PostEra
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Postera
Complete news archive for PostEra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PostEra
PostEra was founded in 2019 and raised its 1st funding round 1 year after it was founded.
PostEra is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Aaron Morris is the current CEO of PostEra. They have also founded this company.
PostEra is a funded company, having raised a total of $26.2M across 2 funding rounds to date.
As of Oct 31, 2021, the latest employee count at PostEra is 3.
AI-based molecular designing software for drug discovery It uses ML technology for designing molecular compounds to aid in the chemical synthesis of the compounds. It also enables the user to explore chemical space and optimize scaffolds of the lead compound, design the synthetic routes. The company also designs and enables users to order chemical compounds.
PostEra's top competitors include Insitro, HotSpot Therapeutics and Certara.
PostEra offers Proton and PostEra Pipeline.
PostEra has 10 investors. Key investors include The Clermont, Breyer Capital, Lifeforce Capital, I2BF Global Ventures, and Metaplanet.